Kappa Opioid Agonists with PEG Moieties for Peripheral Analgesia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current kappa opioid agonists effective for visceral pain often cause central nervous system (CNS) side effects such as dysphoria and sedation, limiting their clinical development, and there is a need for peripherally acting agonists that minimize CNS entry while maintaining analgesic efficacy.
Innovation Solution
Development of novel compounds with specific structural formulas that act as kappa opioid receptor agonists, designed to primarily target peripheral nervous systems with reduced ability to cross the blood-brain barrier, thereby minimizing CNS penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If kappa opioid agonists are used to treat visceral pain, then analgesic efficacy is improved, but CNS side effects (dysphoria and sedation) increase
Solution Approach 1:
The patent applies local quality by modifying specific regions of the kappa opioid agonist molecule. A poly(ethylene glycol) moiety is incorporated at specific positions (R1, R2, or R3) of the molecular scaffold, creating localized hydrophilic regions that reduce CNS penetration while preserving peripheral analgesic activity. This localized modification allows the molecule to maintain therapeutic efficacy at peripheral opioid receptors while minimizing entry into the central nervous system.
Solution Approach 2:
The patent employs parameter changes by altering the lipophilicity and molecular properties of kappa opioid agonists through the incorporation of poly(ethylene glycol) chains. By changing the hydrophilic-lipophilic balance and molecular size parameters, the compounds achieve reduced blood-brain barrier permeability while maintaining sufficient potency at peripheral kappa opioid receptors for effective visceral pain relief.
2Reliability
If kappa opioid agonists enter the CNS to produce analgesia, then pain relief is improved, but dysphoria and sedation worsen
Solution Approach 1:
The patent applies local quality by introducing hydrophilic poly(ethylene glycol) segments at specific locations on the kappa opioid agonist scaffold. These localized hydrophilic regions create steric and solubility barriers that prevent CNS penetration while allowing the molecule to interact with peripheral opioid receptors, thereby producing analgesia without dysphoria or sedation.
Solution Approach 2:
The poly(ethylene glycol) moiety acts as an intermediary element between the hydrophobic core of the kappa opioid agonist and the aqueous physiological environment. This intermediary group modifies the molecule's overall properties to reduce membrane permeability and CNS entry, while still allowing sufficient interaction with peripheral opioid receptors to achieve therapeutic pain relief.
3Object-affected harmful factors
If poly(ethylene glycol) moiety is incorporated to reduce CNS entry, then CNS penetration is reduced, but activity and pharmacological properties may be affected
Solution Approach 1:
The patent applies local quality by strategically placing poly(ethylene glycol) moieties at specific positions (R1, R2, or R3) of the kappa opioid agonist scaffold rather than uniformly modifying the entire molecule. This localized approach allows optimization of CNS penetration reduction while preserving essential pharmacological interactions at peripheral opioid receptors, maintaining analgesic activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying the length and position of poly(ethylene glycol) chains to optimize the balance between reduced CNS penetration and maintained pharmacological activity. By adjusting molecular weight, hydrophilicity, and spatial distribution parameters, the compounds achieve desired peripherally-selective kappa agonist properties.
Data Source
AI summary
Compounds and pharmaceutically acceptable salts and solvates thereof are described. The compounds relate to and/or have application(s) in (among others) the fields of drug discovery, pharmacotherapy, physiology and organic chemistry.